Table 3.

Utilization and labs, 3/1/19–6/30/19 and 3/1/20–6/30/20

Utilization/labs	March 2019	April 2019	May 2019	June 2019
Number of active participants at end of month	3490	3523	3550	3584
Number of unique participants with > 1 encounter	596	682	697	635
% with > 1 encounter	17.1%	19.4%	19.6%	17.7%
Number of encounters, all participants	634	722	769	702
Number of unique participants with HIV RNA test	368	537	603	517
% with > 1 HIV RNA test	10.5%	15.2%	17.0%	14.4%
Number of HIV RNA tests, all participants	570	751	816	702
Number of unique participants with CD4 test	350	537	609	505
Number of CD4 tests, all participants	552	736	810	682

Utilization/labs	March 2020	April 2020	May 2020	June 2020
Number of active participants at end of month	3452	3466	3485	3498
Number of unique participants with > 1 encounter	636	698	740	823
% with > 1 encounter	19.8%	20.1%	212.2%	23.5%
Number of encounters, all participants	686	872	893	963
Number of unique participants with HIV RNA test	381	124	255	399
% with > 1 HIV RNA test	11.0%	3.5%	7.3%	11.4%
Number of HIV RNA tests, all participants	392	131	259	411
Number of unique participants with CD4 test	370	114	253	380
Number of CD4 tests, all participants	401	131	280	419

Utilization/labs	3/1/19–6/30/19	3/1/20–6/30/20
Number of active participants at end of interval	3584	3498
Number of unique participants with > 1 encounter	2610	1997
Number of encounters, all participants	2834	3414
Number of participants with HIV RNA test	2025	1082
Number of HIV RNA tests, all participants	2839	1352
Number of unique participants with CD4 test	2001	1063
Number of CD4 tests, all participants	2780	1193
Proportion with last viral load in interval suppressed (< 50 copies/mL)	79.4%	76.2%

The two proportions with last viral load in interval suppressed between 2019 and 2020 are not equal. The p value is 0.04 and statistically significant